Role of Growth Hormone in Prostate Cancer
Final rept. 19 Jan 2004-18 Jan 2007
ILLINOIS UNIV AT CHICAGO
Pagination or Media Count:
We have established a GH-deficient prostate cancer model TagGhdrdr rat indicating that a reduction in GH andor IGF-I can significantly inhibit prostate carcinogenesis in this model in contrast to GH wild-type controls ProbasinTag, TagGh. TagGh TagGhdrdr and age-matched non-Tag controls were sacrificed at 10, 25 and 52 weeks of age. While real-time RT PCR and immunohistochemical analysis revealed the significantly increased levels of prostate GHR and the dramatically reduced levels of prostate IGF-1R P0.0001 in TagGh during prostate cancer progression the loss of prostate GHR and the increase of IGF-1R were observed in TagGhdrdr. However there was no significant change in either serum or prostate IGF-1 level that can be correlated with prostate cancer progression or the resistance of TagGhdrdr to prostate carcinogenesis. These findings are consistent with the hypothesis that GH signaling plays a significant role in prostate carcinogenesis and suggest that GH antagonists may be effective agent against prostate cancer.
- Medicine and Medical Research